BioPorto A/S (CPH:BIOPOR)

Market Cap	591.66M -0.8%
Revenue (ttm)	40.29M +11.2%
Net Income	-82.12M
EPS	-0.15
Shares Out	495.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	174,019
Open	1.160
Previous Close	1.195
Day's Range	1.150 - 1.195
52-Week Range	0.839 - 1.488
Beta	1.38
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About BioPorto

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnos...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1917
• Employees: 46
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: BIOPOR

Financial Performance

In 2025, BioPorto's revenue was 40.29 million, an increase of 11.16% compared to the previous year's 36.24 million. Losses were -82.12 million, 20.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 17, 2026

Data Sources Report a data error